Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
liposomal cytarabine
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Intrathecal DepoCyte and Lineage-Targeted Minimal Residual Disease-Oriented Therapy of Acute Lymphoblastic Leukemia
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
NILG-ALL 10/07
, NCT00795756
2.
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2005-0135
, NCT00515788
3.
Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
BIDMC-2003P-000182
, NCT00073957
4.
Phase II Study of Rituximab, Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, and High-Dose Methotrexate (R-CODOX-M) Alone or Alternating With Rituximab and Ifosfamide, Etoposide Phosphate, and High-Dose Cytarabine (IVAC) in Combination With Intrathecal CNS Prophylaxis in Patients With Newly Diagnosed, HIV-Associated Burkitt's or Atypical Burkitt's Lymphoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AMC-048
, AMC-048, NCT00392834
5.
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2004-004414-17
, DEPOCYLAN, NCT00388531
6.
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-Cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
R-C5R 2006
, R-C5R, NCT00553943
7.
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
19 to 65
Sponsor:
Other
Protocol IDs:
SCNSL1
, IIL-SCNSL-1, NCT00801216
8.
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
Phase:
Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2008-007206-10
, DEP1501, NCT00854867
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute